Syngenta obtains first regulatory approvals for new fungicide Revus™

Basel, Switzerland, October 3, 2006 - Syngenta announced today that its new fungicide Revus™, developed under the code 446, has received its first registrations in Europe (Austria) and Asia (South Korea). Further registrations in other markets are targeted for the 2007 season. Global peak sales are expected to exceed $100 million annually.

Revus sets new standards providing best-in-class, weatherproof and long-lasting protection against late blight in potatoes and tomatoes, as well as downy mildew in vines and vegetable crops. Results from a large number of field trials conducted around the world show that Revus provides consistent performance even under extreme disease pressure.

“Revus is a significant innovation for growers. This new technology further strengthens Syngenta’s leading fungicide portfolio for high-value crops offering growers a complete range of disease control solutions” said John Atkin, Chief Operating Officer of Syngenta Crop Protection. “We already successfully launched two new products, Axial® and Avicta®, for the 2006 season, Revus is the third and we have another five crop protection products planned for launch by 2012.”

Syngenta is a world-leading agribusiness committed to sustainable agriculture through innovative research and technology. The company is a leader in crop protection, and ranks third in the high-value commercial seeds market. Sales in 2005 were approximately $8.1 billion. Syngenta employs more than 19,000 people in over 90 countries. Syngenta is listed on the Swiss stock exchange (SYNN) and in New York (SYT). Further information is available at www.syngenta.com.

Cautionary Statement Regarding Forward-Looking Statements
This document contains forwarding-looking statements, which can be identified by terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta’s publicly available filings the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issues, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta, AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in a connection with, any contract therefor.

Contact Information

Médard Schoenmaeckers

Media Enquiries

Syngenta

Contact via E-mail